



### AMPLIS GUIDANCE

This report combines (i) an analysis of the patient's DNA by Luminus Diagnostics identifying relevant genetic variants (ii) antidepressant guidance utilizing blood brain barrier genetics, and (iii) an interpretation of the identified DNA variants. Combining depression medication guidance with genetic variant information provides information on how a patient metabolizes medications with guidance on treating patients with existing depression medications.

Patient: DOE, JANE  
 Date of Birth: Aug 26, 1982  
 Gender: Female

Physician: TEST  
 Practice: LUMINUS DIAGNOSTICS

Date Collected: Oct 11, 2017  
 Date Accessioned: Oct 11, 2017  
 Specimen type: BU  
 Sample ID: 1710111111

## DEPRESSION MEDICATION GUIDANCE

### LOWER DOSE LESS PREFERRED

Genetically for this patient the below antidepressants appear tolerable and effective at the very low end of the recommended dose range.\*

Agomelatine (Valdoxan®)  
 Reboxetine (Edronax®)  
 Vilazodone (Viibryd®)  
 Desvenlafaxine (Pristiq®)  
 Levomilnacipran (Fetzima®)

### AVERAGE DOSE PREFERRED

Genetically for this patient the below antidepressants appear tolerable and effective at average recommended doses, so may be preferred.\*

Citalopram (Celexa®)  
 Clomipramine (Anafranil®)  
 Escitalopram (Lexapro®)  
 Fluvoxamine (Luvox®)  
 Nortriptyline (Pamelor®)

### HIGHER DOSE LESS PREFERRED

Genetically for this patient the below antidepressants appear tolerable and effective at the very high end of the recommended dose range. Upward dose titration may be clinically appropriate.\*

Trazodone (Desyrel®)  
 Amitriptyline (Elavil®)  
 Mirtazapine (Remeron®)

## PHARMACOGENETIC RESPONSE REPORT

### Luminus Live Gene Rx

Individualized, additional therapeutic decision support information based on JANE DOE's genetics, drug regimen, indications, demographics, and lifestyle indicators are available at Luminus Live Gene Rx via this secured URL:  
<https://app.luminuslive.com/?token=prompt>

Luminus Live Key: AH22WGWMY  
 Sample ID: 1710111111

### Genetic Summary

Gene	Activity †	Gene	Activity †
ANKK1	Normal function	CYP3A4	Poor metabolizer
COMT(Val158Met)	Normal function	CYP3A5	Poor metabolizer
CYP1A2	Extensive Metabolizer, Ultrarapid Metabolizer, Unknown Metabolizer	CYP4F2	Poor metabolizer
CYP2B6	Extensive metabolizer	Factor II	See thrombosis profile
CYP2C19	Intermediate metabolizer	Factor V Leiden	See thrombosis profile
CYP2C9	Poor metabolizer, Not EM	MTHFR (A1298C)	See thrombosis profile
CYP2D6	Intermediate metabolizer	MTHFR (C677T)	See thrombosis profile
		OPRM1(A118G)	Normal function

1710111111 - DOE, JANE - Reported Nov 28, 2017

## Current Regimen Risk Chart

This chart summarizes the various risk factors associated with each medication entered into Luminus Live Gene Rx for JANE DOE. The length of each colored segment represents the relative contribution of a risk category (detailed in the below legend) to the overall risk associated with the use of a medication. For further information, consult the [Current Regimen Risk Details Pg. 4](#) section.

For further assistance in choosing alternative medications to reduce this patient's risk, use the modeling tool at <https://app.luminuslive.com/?token=prompt>.

